V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220013917 | 220008353 | 1.84 | null | Disease modification (D) | 2014-04-27 | 2014-06-07 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220031700 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013918 | 220008353 | 1.69 | 87.5 | Curative (C) | null | 2014-04-29 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220031700 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013919 | 220008353 | 1.64 | 72 | Curative (C) | 2018-02-16 | 2018-02-18 | FLAG | 2 | N | 220031700 | FLAG |
| 220013920 | 220008353 | 1.72 | 54 | Curative (C) | 2016-09-09 | 2016-09-09 | Triple Intrathecal | N | N | 220031700 | TRIPLE INTRATHECAL |
| 220013921 | 220008355 | 1.68 | 74.5 | Curative (C) | 2013-07-28 | 2013-07-28 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031722 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013922 | 220014535 | 1.68 | 66.2 | Palliative (P) | 2014-06-08 | 2014-10-12 | Cyclophosphamide+Fludara+TBI Allo | 2 | N | 220031724 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013923 | 220014535 | 1.73 | 77.4 | Curative (C) | null | 2015-05-24 | ATG + Busulfan + Fludarabine | N | N | 220031724 | ATG + BUSULFAN + FLUDARABINE |
| 220013924 | 220008356 | 1.79 | 80 | Curative (C) | 2016-10-16 | 2016-10-22 | Triple Intrathecal | N | N | 220031734 | TRIPLE INTRATHECAL |
| 220013925 | 220008358 | null | 71.45 | Disease modification (D) | 2013-08-12 | 2013-08-12 | Cyclophosphamide TBI Allograft | null | null | 220031735 | CYCLOPHOSPHAMIDE |
| 220013926 | 220008360 | null | 127 | Curative (C) | 2013-05-29 | 2013-05-29 | FLAG | N | null | 220031736 | FLAG |
| 220013927 | 220008362 | 1.86 | 89.4 | null | 2013-04-01 | 2013-04-01 | Cyclophosphamide oral | Y | N | 220031736 | CYCLOPHOSPHAMIDE |
| 220013928 | 220008362 | 1.66 | 63.2 | Curative (C) | 2013-04-19 | 2013-04-19 | Triple Intrathecal | N | N | 220031736 | TRIPLE INTRATHECAL |
| 220013930 | 220008365 | null | 67 | Curative (C) | 2015-02-01 | 2015-02-01 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031748 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013931 | 220008366 | 1.7 | 71.8 | Curative (C) | 2013-10-18 | 2013-11-22 | Triple / Double Intrathecal Therapy | 2 | N | 220031749 | TRIPLE INTRATHECAL |
| 220013932 | 220014541 | 1.75 | 0 | Curative (C) | 2017-07-07 | 2017-07-13 | FLAG | N | N | 220031749 | FLAG |
| 220013933 | 220020947 | 1.67 | 69.4 | Curative (C) | 2018-11-06 | 2018-11-06 | BOSUTINIB | Y | N | 220031756 | BOSUTINIB |
| 220013934 | 220008368 | 1.96 | 88.9 | Curative (C) | 2016-03-25 | 2016-04-01 | Methotrexate intrathecal | N | N | 220031759 | METHOTREXATE INTRATHECAL |
| 220013935 | 220008369 | 1.65 | 13.9 | Curative (C) | 2014-01-16 | 2014-01-16 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031774 | ADE |
| 220013936 | 220014542 | 1.77 | 95.6 | null | 2014-03-15 | 2014-05-17 | BOSUTINIB | null | null | 220031774 | BOSUTINIB |
| 220013937 | 220008371 | 1.8 | 7.1 | Curative (C) | 2018-01-01 | 2018-02-09 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031784 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013938 | 220008372 | 1.71 | 50.4 | Curative (C) | 2014-10-07 | 2014-10-07 | FLAG | N | N | 220031790 | FLAG |
| 220013939 | 220008373 | 0 | 6.6 | Curative (C) | null | 2013-04-06 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031792 | ADE |
| 220013940 | 220008376 | null | 6.5 | Adjuvant (A) | 2016-05-02 | 2016-05-12 | Idarubicin+Tretinoin Spanish Crse2 | N | null | 220031796 | IDARUBICIN + TRETINOIN |
| 220013941 | 220008377 | null | 89 | null | null | 2018-02-12 | ATG + Busulfan + Fludarabine | null | N | 220031796 | ATG + BUSULFAN + FLUDARABINE |
| 220013942 | 220008380 | null | 80 | Curative (C) | 2013-12-08 | 2013-12-08 | Idarubicin+Tretinoin Spanish Crse1 | 2 | N | 220031799 | IDARUBICIN + TRETINOIN |
| 220013943 | 220008382 | null | 83.3 | Curative (C) | null | 2016-09-29 | BOSUTINIB | Y | null | 220031811 | BOSUTINIB |
| 220013944 | 220008382 | 1.51 | 58.7 | Curative (C) | 2017-01-12 | 2017-01-16 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031811 | ADE |
| 220013945 | 220008387 | 1.55 | 54.7 | Curative (C) | 2018-01-11 | 2018-09-20 | BOSUTINIB | N | N | 220031813 | BOSUTINIB |
| 220013950 | 220014548 | 1.58 | 43.4 | Not known (9) | 2013-12-26 | 2013-12-26 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220031821 | IDARUBICIN + TRETINOIN |
| 220013951 | 220008394 | 1.73 | 68.8 | Disease modification (D) | 2014-05-11 | 2014-05-18 | BOSUTINIB | N | N | 220031822 | BOSUTINIB |
| 220013952 | 220008394 | 1.61 | 61.2 | Palliative (P) | 2017-10-22 | 2017-11-21 | CYCLOPHOSPHAMIDE | null | N | 220031822 | CYCLOPHOSPHAMIDE |
| 220013953 | 220008395 | 1.49 | 46 | Palliative (P) | 2013-11-08 | 2013-12-24 | RUXOLITINIB | 02 | N | 220031843 | RUXOLITINIB |
| 220013954 | 220008395 | null | 20 | null | 2015-04-27 | 2015-06-17 | Triple / Double Intrathecal Therapy | null | N | 220031843 | TRIPLE INTRATHECAL |
| 220013955 | 220008395 | 1.98 | 69.9 | Palliative (P) | 2016-04-17 | 2016-04-22 | BOSUTINIB | N | N | 220031843 | BOSUTINIB |
| 220013956 | 220008396 | null | 98.75 | Disease modification (D) | 2017-12-07 | 2017-12-07 | RUXOLITINIB | N | N | 220031869 | RUXOLITINIB |
| 220013957 | 220014551 | 0 | 93 | Palliative (P) | 2015-10-15 | 2015-10-18 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220031869 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013958 | 220008398 | 1.74 | 155 | Palliative (P) | 2015-02-14 | 2015-02-14 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220031877 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013959 | 220008399 | 1.84 | 17.5 | Adjuvant (A) | 2017-06-20 | 2017-06-21 | FLAG | N | N | 220031880 | FLAG |
| 220013960 | 220014553 | 1.6 | 0 | null | 2014-05-07 | 2014-06-06 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031880 | ADE |
| 220013961 | 220008401 | 1.56 | 83.8 | Palliative (P) | 2016-10-05 | 2017-07-23 | BOSUTINIB | N | N | 220031887 | BOSUTINIB |
| 220013962 | 220008402 | null | 93 | null | 2015-09-12 | 2015-09-12 | BOSUTINIB | 02 | N | 220031890 | BOSUTINIB |
| 220013963 | 220014554 | 1.75 | 78.4 | Disease modification (D) | 2017-07-13 | 2017-07-13 | Idarubicin+Tretinoin Spanish Crse2 | N | null | 220031890 | IDARUBICIN + TRETINOIN |
| 220013964 | 220008403 | 0 | 68.1 | Disease modification (D) | 2015-06-09 | 2015-06-09 | RUXOLITINIB | N | N | 220031895 | RUXOLITINIB |
| 220013965 | 220008405 | 1.63 | 41.9 | Disease modification (D) | 2015-09-20 | 2016-09-06 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031907 | ADE |
| 220013966 | 220014557 | 0 | 97 | null | 2016-07-14 | 2016-07-17 | Idarubicin+Tretinoin Spanish Crse4 | N | null | 220031911 | IDARUBICIN + TRETINOIN |
| 220013967 | 220017955 | null | 60 | Disease modification (D) | 2016-02-12 | 2016-02-12 | ATG + Busulfan + Fludarabine | 99 | N | 220031916 | ATG + BUSULFAN + FLUDARABINE |
| 220013968 | 220017955 | 1.62 | 94.6 | Adjuvant (A) | 2014-07-27 | 2014-07-27 | Methotrexate intrathecal | 2 | N | 220031916 | METHOTREXATE INTRATHECAL |
| 220013969 | 220008407 | 1.68 | 60.3 | Curative (C) | 2012-12-21 | 2013-10-10 | CYCLOPHOSPHAMIDE | 02 | Y | 220031919 | CYCLOPHOSPHAMIDE |
| 220013970 | 220008411 | 0 | null | Disease modification (D) | 2016-12-26 | 2017-02-09 | BOSUTINIB | N | N | 220031932 | BOSUTINIB |
| 220013971 | 220008412 | 1.72 | 88.3 | Curative (C) | 2016-03-27 | 2016-04-02 | Methotrexate intrathecal | N | N | 220031935 | METHOTREXATE INTRATHECAL |